Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic

NCT01643278 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

NIH

Sponsor class

Conditions

Gastrointestinal Stromal Tumor
Stage III Soft Tissue Sarcoma
Stage IV Soft Tissue Sarcoma

Interventions

DRUG: Dasatinib
BIOLOGICAL: Ipilimumab
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)